---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-230906"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:33:24.041911+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# KalVista appoints Bilal Arif as COO and Linea Aspesi as Chief People Officer

## Summary
- Bilal Arif appointed COO effective Oct 6, 2025; base salary $520k, annual bonus target 40%, option grant of 100,000 shares.
- Linea Aspesi appointed Chief People Officer; also receives inducement option grant of 100,000 shares.
- Both options vest over 4 years: 1/4th on 1-year anniversary, then monthly vesting.
- Appointments support global launch of EKTERLY for hereditary angioedema.
- Arif was EVP at Sarepta Therapeutics; Aspesi was Chief Admin Officer at Editas Medicine.

## SEC filing metadata
- accession: 0001193125-25-230906
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312525230906/0001193125-25-230906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312525230906/d42627d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-230906
- JSON: https://secwatch.observer/filing/0001193125-25-230906.json
- Plain text: https://secwatch.observer/filing/0001193125-25-230906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.